Piper Sandler lowered the firm’s price target on Context Therapeutics (CNTX) to $4 from $4.50 and keeps an Overweight rating on the shares after assuming coverage. Context Therapeutics is focused on the emerging T-cell engager modality, which has been validated by several recent clinical milestones and strategic acquisitions, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTX:
- Context Therapeutics Approves Reverse Stock Split Amendment
- Context Therapeutics Highlights T Cell Engager Advancements
- Context Therapeutics appoints Chagin as Chief Medical Officer
- Promising Progress in Context Therapeutics’ Cancer Treatment Advances: Buy Rating Affirmed
- Optimistic Buy Rating on Context Therapeutics Amid Promising Program Developments and Undervaluation